Finding the sweet spot in managing diabetes with coronary artery disease and chronic kidney disease: Pharmacotherapy pearls with a focus on sodium-glucose cotransporter-2 inhibitors.
作者信息
Trischuk Taisa, Laubscher Tessa, Regier Loren
机构信息
Pharmacist for the RxFiles Academic Detailing Program at the University of Saskatchewan in Saskatoon.
Clinical Associate Professor of Academic Family Medicine at the University of Saskatchewan.
出版信息
Can Fam Physician. 2020 May;66(5):341-346.
Abstract
摘要
相似文献
1
2
Risk of hospitalization with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes lacking evidence of chronic kidney disease: Real-world data.2型糖尿病且无慢性肾脏病证据患者中，钠-葡萄糖协同转运蛋白2抑制剂与二肽基肽酶-4抑制剂相比的住院风险：真实世界数据
Diabetes Obes Metab. 2023 Oct;25(10):3054-3058. doi: 10.1111/dom.15172. Epub 2023 Jun 29.
3
[Clinical and practical management of sodium-glucose cotransporter type 2 inhibitors in patients with chronic kidney disease].[慢性肾脏病患者中钠-葡萄糖协同转运蛋白2抑制剂的临床与实际管理]
Semergen. 2023 Jun;49 Suppl 1:102020. doi: 10.1016/j.semerg.2023.102020.
4
Sodium-glucose cotransporter 2 inhibitor-induced reduction in the mean arterial pressure improved renal composite outcomes in type 2 diabetes mellitus patients with chronic kidney disease: A propensity score-matched model analysis in Japan.钠-葡萄糖共转运蛋白 2 抑制剂降低平均动脉压可改善合并慢性肾脏病的 2 型糖尿病患者的肾脏复合结局：日本倾向评分匹配模型分析。
J Diabetes Investig. 2021 Aug;12(8):1408-1416. doi: 10.1111/jdi.13491. Epub 2021 Feb 1.
5
Expanding the Impact of SGLT2 Inhibitors in Chronic Kidney Disease.扩大钠-葡萄糖协同转运蛋白2抑制剂在慢性肾脏病中的影响
Am J Nephrol. 2024;55(4):417-420. doi: 10.1159/000536540. Epub 2024 Feb 28.
6
Narrative review investigating the nephroprotective mechanisms of sodium glucose cotransporter type 2 inhibitors in diabetic and nondiabetic patients with chronic kidney disease.综述探讨钠-葡萄糖共转运蛋白 2 抑制剂在糖尿病和非糖尿病慢性肾脏病患者中的肾保护机制。
Front Endocrinol (Lausanne). 2023 Dec 20;14:1281107. doi: 10.3389/fendo.2023.1281107. eCollection 2023.
7
Time to clinical benefit with sotagliflozin in patients with type 2 diabetes and chronic kidney disease: Insights from the SCORED randomized trial.索格列净治疗2型糖尿病合并慢性肾脏病患者达到临床获益的时间：来自SCORED随机试验的见解
Eur J Heart Fail. 2024 Apr;26(4):1093-1095. doi: 10.1002/ejhf.3240. Epub 2024 Apr 17.
8
Focused Updates: SGLT2 Inhibitors in Patients With Heart Failure and/or Chronic Kidney Disease.重点更新：心力衰竭和/或慢性肾脏病患者的 SGLT2 抑制剂。
Ann Pharmacother. 2021 Feb;55(2):252-260. doi: 10.1177/1060028020934001. Epub 2020 Jun 13.
9
Management of type 2 diabetes in chronic kidney disease.2 型糖尿病合并慢性肾脏病的管理。
BMJ Open Diabetes Res Care. 2021 Jul;9(1). doi: 10.1136/bmjdrc-2021-002300.
10
SGLT-2 inhibitors: Diabetes and CKD and CHF (and gout?), oh my!钠-葡萄糖协同转运蛋白2抑制剂：糖尿病、慢性肾脏病和心力衰竭（还有痛风？），天哪！
Cleve Clin J Med. 2024 Jul 1;91(7):392-393. doi: 10.3949/ccjm.91b.07024.
本文引用的文献
1
CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis.CCS/CHFS 心力衰竭指南：功能性二尖瓣反流、SGLT2 抑制剂、HFpEF 中的 ARNI 以及淀粉样变中的塔法米迪的临床试验更新。
Can J Cardiol. 2020 Feb;36(2):159-169. doi: 10.1016/j.cjca.2019.11.036.
2
2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).2019 年更新版：《2018 年美国糖尿病协会（ADA）与欧洲糖尿病研究协会（EASD）关于 2 型糖尿病患者高血糖管理的共识报告》。
Diabetes Care. 2020 Feb;43(2):487-493. doi: 10.2337/dci19-0066. Epub 2019 Dec 19.
3
Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial.利格列汀与格列美脲对2型糖尿病患者主要不良心血管结局的影响：卡罗来纳州随机临床试验
JAMA. 2019 Sep 24;322(12):1155-1166. doi: 10.1001/jama.2019.13772.
4
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.度拉糖肽与 2 型糖尿病患者的心血管结局（REWIND）：一项双盲、随机、安慰剂对照试验。
Lancet. 2019 Jul 13;394(10193):121-130. doi: 10.1016/S0140-6736(19)31149-3. Epub 2019 Jun 9.
5
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.卡格列净与 2 型糖尿病和肾病患者的肾脏结局。
N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14.
6
Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.比较胰高血糖素样肽受体激动剂和钠-葡萄糖共转运蛋白 2 抑制剂在 2 型糖尿病患者预防主要不良心血管和肾脏结局的效果。
Circulation. 2019 Apr 23;139(17):2022-2031. doi: 10.1161/CIRCULATIONAHA.118.038868.
7
American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults.美国老年医学学会 2019 年更新的老年人潜在不适当药物使用 AGS Beers 标准®。
J Am Geriatr Soc. 2019 Apr;67(4):674-694. doi: 10.1111/jgs.15767. Epub 2019 Jan 29.
8
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.SGLT2 抑制剂用于 2 型糖尿病的心血管和肾脏结局的一级和二级预防：心血管结局试验的系统评价和荟萃分析。
Lancet. 2019 Jan 5;393(10166):31-39. doi: 10.1016/S0140-6736(18)32590-X. Epub 2018 Nov 10.
9
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.利拉利汀对比安慰剂对伴有高心血管和肾脏风险的 2 型糖尿病成人患者主要心血管事件的影响：CARMELINA 随机临床试验。
JAMA. 2019 Jan 1;321(1):69-79. doi: 10.1001/jama.2018.18269.
10
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.达格列净与 2 型糖尿病患者的心血管结局
N Engl J Med. 2019 Jan 24;380(4):347-357. doi: 10.1056/NEJMoa1812389. Epub 2018 Nov 10.
Zotero 插件